{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T02:16:21Z","timestamp":1758420981611,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[1998,6,30]]},"published-print":{"date-parts":[[1998,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess procedural outcome, complications, and clinical follow up in 218 patients who underwent treatment with 297 Multi-link (Guidant) stents implanted without the use of intravascular ultrasound (IVUS) or quantitative coronary angiography (QCA), and using aspirin alone as antiplatelet therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec sec-type=\"methods\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The case records and angiograms were reviewed and the patients were contacted by telephone to determine their symptoms and any adverse events at follow up. Data were analysed using Fisher\u2019s exact test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 218 patients included in the study, 45 had multivessel intracoronary intervention, and 55 had unstable angina. The mean (SD) length of hospital stay following the procedure was 2.0 (2.1) days. There were two early deaths at less than 30 days, and two deaths during follow up at more than 100 days. Ten patients suffered complications during the first 30 days: four had subacute stent thrombosis, of whom two died and two were treated successfully with coronary artery bypass grafting; five had a non-Q wave myocardial infarction; and one had a femoral false aneurysm. Patient outcome was analysed according to stent diameter (3.0\u2009mm or less, or 3.5\u2009mm or more) and by angina status (stable or unstable). In patients in whom at least one stent was 3.0\u2009mm diameter, four of 86 patients suffered acute stent occlusion, whereas in the 132 patients in whom all stents were at least 3.5\u2009mm diameter there were no cases of stent occlusion (p\u2009=\u20090.02). In the unstable angina group two of 55 patients suffered acute stent occlusion compared to two of 163 patients in the stable angina group (NS). In patients with unstable angina and at least one stent of 3.0\u2009mm diameter, the acute occlusion rate was 7.1% (two of 28 patients). Three of the four patients with stent occlusion had undergone complex procedures. Twenty eight patients were restudied for recurrent symptoms during the follow up period. Of these, eight patients had restenosis within their stent. In seven of these patients the stent size was 3.0\u2009mm diameter, and in the remaining patient the stent size was 4.0\u2009mm diameter. Three of the 28 patients restudied had developed new disease remote from the stented site, and 17 had patent stents and no significant other coronary lesion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study suggests that coronary intervention using the Multi-link stent is safe and effective using aspirin alone, without IVUS or QCA, when stent diameter is greater than 3.0\u2009mm. All cases of stent occlusion in this series occurred in patients in whom at least one stent was 3.0\u2009mm diameter, with stent occlusion being higher in patients with unstable angina compared to those with stable angina. Additional antiplatelet therapy may be beneficial in those patients in whom Multi-link stent diameter is less than 3.5\u2009mm, particularly in those with unstable angina, but is not necessary for patients receiving Multi-link stents of 3.5\u2009mm diameter or greater.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/hrt.80.5.499","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T15:31:45Z","timestamp":1413991905000},"page":"499-504","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Intracoronary Multi-link stents: experience in 218 patients using aspirin alone"],"prefix":"10.1136","volume":"80","author":[{"given":"A L","family":"Calver","sequence":"first","affiliation":[{"name":"Wessex Cardiothoracic Unit, Southampton University Hospital, Tremona Road, Southampton  SO16 6YD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K D","family":"Dawkins","sequence":"additional","affiliation":[{"name":"Wessex Cardiothoracic Unit, Southampton University Hospital, Tremona Road, Southampton  SO16 6YD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H H","family":"Gray","sequence":"additional","affiliation":[{"name":"Wessex Cardiothoracic Unit, Southampton University Hospital, Tremona Road, Southampton  SO16 6YD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G A","family":"Haywood","sequence":"additional","affiliation":[{"name":"Wessex Cardiothoracic Unit, Southampton University Hospital, Tremona Road, Southampton  SO16 6YD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Morgan","sequence":"additional","affiliation":[{"name":"Wessex Cardiothoracic Unit, Southampton University Hospital, Tremona Road, Southampton  SO16 6YD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I A","family":"Simpson","sequence":"additional","affiliation":[{"name":"Wessex Cardiothoracic Unit, Southampton University Hospital, Tremona Road, Southampton  SO16 6YD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1998,11,1]]},"reference":[{"key":"2025092014004944000_80.5.499.1","first-page":"183","article-title":"Changing incidence and management of abrupt closure following coronary intervention in the new device era.","volume":"27","author":"Kuntz","year":"1992","journal-title":"Cath Cardiovasc Diag"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.2","DOI":"10.1161\/01.CIR.85.3.916"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.3","DOI":"10.1056\/NEJM199408253310801"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.4","DOI":"10.1056\/NEJM199408253310802"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.5","DOI":"10.1016\/0735-1097(94)90099-X"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.6","DOI":"10.1056\/NEJM198703193161201"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.7","DOI":"10.1161\/01.CIR.91.6.1676"},{"key":"2025092014004944000_80.5.499.8","first-page":"I-796","article-title":"Coronary stenting without anticoagulant, without intravascular ultrasound. Results of the French registry.","volume":"92","author":"Morice","year":"1995","journal-title":"Circulation"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.9","DOI":"10.1056\/NEJM199604253341702"},{"unstructured":"(1997) Ticlopidine and white blood cell disorders. Current problems in pharmacovigilance. (Medicines Control Agency, London) ;23:2.","key":"2025092014004944000_80.5.499.10"},{"doi-asserted-by":"crossref","unstructured":"Harker LA Bruno JB (1993) Ticlopidine\u2019s mechanism of action on human platelets. in Ticlopidine, platelets and vascular disease. eds Hass WK Easton JD (Springer-Verlag, New York), pp 41\u201359.","key":"2025092014004944000_80.5.499.11","DOI":"10.1007\/978-1-4613-8306-2_4"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.12","DOI":"10.1016\/S0735-1097(96)00428-7"},{"unstructured":"van der Giessen W, Emanuelsson H, Dawkins K, et al. Clinical and angiographic results with the Multi-linkTM coronary stent system. The west European stent trial (WEST) [abstract]. Eur Heart J1996;17(suppl 22):19.","key":"2025092014004944000_80.5.499.13"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.14","DOI":"10.1161\/01.CIR.91.12.2995"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.15","DOI":"10.1136\/hrt.76.4.344"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.16","DOI":"10.1161\/01.CIR.83.3.927"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.17","DOI":"10.1161\/01.CIR.93.2.215"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.18","DOI":"10.1016\/S0140-6736(97)22003-9"},{"key":"2025092014004944000_80.5.499.19","first-page":"I-593","article-title":"ACS Multi-linkTM stent clinical equivalence in de novo lesions trial (ASCENT) [abstract].","volume":"96","author":"Baim","year":"1997","journal-title":"Circulation"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.20","DOI":"10.1002\/(SICI)1098-1128(199603)16:2<159::AID-MED2>3.0.CO;2-#"},{"doi-asserted-by":"publisher","key":"2025092014004944000_80.5.499.21","DOI":"10.1016\/S0140-6736(96)09457-3"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/hrt.80.5.499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:00:57Z","timestamp":1758402057000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/hrt.80.5.499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11,1]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1998,11,1]]},"published-print":{"date-parts":[[1998,11,1]]}},"alternative-id":["10.1136\/hrt.80.5.499"],"URL":"https:\/\/doi.org\/10.1136\/hrt.80.5.499","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[1998,11,1]]}}}